12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Tuesday's pre-market session, health care stocks saw significant movements. Janux Therapeutics and Viking Therapeutics led the gainers with over 90% increases in their stock prices, while NRX Pharmaceuticals and Veradigm were among the top losers, experiencing over 20% declines. Notably, TransMedics, Ligand Pharmaceuticals, and Hims & Hers Health reported their Q4 earnings, influencing their stock movements.
February 27, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Janux Therapeutics stock surged 120.5% to $33.3, with a market cap of $1.5 billion.
The significant surge in Janux Therapeutics' stock price likely reflects investor optimism, possibly due to recent company developments or market conditions favoring the health care sector.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
TransMedics stock rose 22.2% to $95.0 following their Q4 earnings report, with a market cap of $3.1 billion.
The positive reaction in TransMedics' stock price post-Q4 earnings suggests the report exceeded market expectations, indicating strong company performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Viking Therapeutics shares increased by 97.24% to $75.9, with a market cap of $7.6 billion.
Viking Therapeutics' significant stock price increase suggests strong investor confidence, potentially due to favorable company news or broader sector trends.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Veradigm shares decreased by 22.03% to $6.48, with a market value of their outstanding shares at $708.0 million.
The decrease in Veradigm's stock price suggests negative market reaction, potentially due to unfavorable company developments or market conditions.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
NRX Pharmaceuticals shares decreased by 22.9% to $0.33, with a market cap of $28.0 million.
The sharp decline in NRX Pharmaceuticals' stock price indicates negative investor sentiment, possibly due to disappointing company news or broader market trends.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100